Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

87 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate the use of a new drug targeting the DNA repair pathway AZD6738, an ATR inhibitor). Many tumours have lost important DNA repair functions and rely more heavily on a few remaining repair pathways to survive. Preclinical studies indicate that, in these tumours, preventing the function of the remaining pathways will lead to tumour cell death, while sparing normal cells. This study aims to investigate the safety and tolerability of the new drug in patients with advanced cancer, as well as in combination with palliative radiotherapy, where the drug may increase the effectiveness of radiotherapy by preventing repair of the radiationinduced DNA damage. As the drug has only been given to a small number of patients, the study will focus on safety and finding the correct dose to proceed to further studies, although preliminary signs of drug activity will also be examined.

The initial part of the study will administer increasing doses of the drug to groups of patients with advanced cancer who have no standard anticancer treatment options available. Testing will establish whether the drug levels in the body and tumour are adequate for the drug to have an effect, and any toxicity will be assessed. After the recommended dose is established, the recommended dose schedule will be stablished by trialing different schedules. Participants will be tested to see if their tumours lack the main DNA repair pathway (those who are predicted to have a better response to this drug). Finally, the drug will be given to patients with advanced cancer who require a course of radiotherapy for symptom control - the drug will be tested at different doses and with different doses of radiotherapy.

Side effects will be monitored and tests will establish whether the drug is enhancing the radiotherapy effect in the tumours or normal tissues.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

NCT01021748

Locally Advanced or Metastatic Solid Tumors

COMPLETED PHASE1

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

NCT00782574

Advanced Solid Tumors

COMPLETED PHASE1

AZD6738 & Gemcitabine as Combination Therapy

NCT03669601

Cancer

UNKNOWN PHASE1

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

NCT02630199

Refractory Cancer

COMPLETED PHASE1

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

NCT00600496

Breast Cancer Breast Neoplasms Colon Cancer +5 more

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumour Refractory to Conventional Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose Escalation

AZD6738 PO 20 to 380mg BD increasing

Group Type EXPERIMENTAL

AZD6738

Intervention Type DRUG

AZD6738 - Expansion Phase

AZD6738 starting dose and regimen to be determined in dose escalation phase

Group Type EXPERIMENTAL

AZD6738

Intervention Type DRUG

AZD6738 + Radiotherapy (Head and Neck)

AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)

Group Type EXPERIMENTAL

AZD6738

Intervention Type DRUG

Palliative radiotherapy

Intervention Type RADIATION

AZD6738 + Radiotherapy (Abdomen / Pelvis)

AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)

Group Type EXPERIMENTAL

AZD6738

Intervention Type DRUG

Palliative radiotherapy

Intervention Type RADIATION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD6738

Intervention Type DRUG

Palliative radiotherapy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically documented solid tumour refractory to conventional treatment
* Evidence of measurable or evaluable disease by RECIST 1.1
* Age must be 18 years or over.
* ECOG performance status 0-1 (part A); 0-2 (parts B and C)
* Life expectancy of at least 3 months.
* Patients must have normal organ and bone marrow function measured within 7 days prior to administration of study treatment as defined below:
* Signed informed consent indicating that the subject is aware of the neoplastic nature of their disease and have been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts.
* Willing and able to comply with scheduled visits, tissue sampling, treatment plan, and laboratory tests.
* Able to swallow, absorb and retain oral medication.

Exclusion Criteria

* Therapy with any other investigational medical product (IMP) concurrently or within 28 days prior to signing of consent.
* Pregnant or breast-feeding women.
* Ability to become pregnant (or already pregnant or lactating).
* Clinically significant cardiac disease including:
* Known HIV positive or active hepatitis B or C infection
* Uncontrolled active infection
* Symptomatic and progressive or steroid-requiring brain metastases or leptomeningeal disease involvement.
* Uncontrolled hypertension requiring clinical intervention, hypertension requiring 2 or more antihypertensive agents
* Dementia or altered mental status that would prohibit informed consent.
* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Principal Investigator, would make the subject inappropriate for this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No